1. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation
- Author
-
Uma Malhotra, Peter B. Gilbert, Juliana M. McElrath, Ann Duerr, Natalie Hawkins, Steven G. Self, Fusheng Li, and Lawrence Corey
- Subjects
Vaccine evaluation ,HIV Antigens ,Molecular Sequence Data ,Virus ,Epitope ,Epitopes ,Databases, Genetic ,Humans ,Cytotoxic T cell ,Amino Acid Sequence ,AIDS Vaccines ,Immunity, Cellular ,General Veterinary ,General Immunology and Microbiology ,biology ,Immunogenicity ,Public Health, Environmental and Occupational Health ,biology.organism_classification ,Virology ,CTL ,Infectious Diseases ,Lentivirus ,HIV-1 ,Molecular Medicine ,Viral disease ,Peptides ,Algorithms ,T-Lymphocytes, Cytotoxic - Abstract
Dozens of human immunodeficiency virus-type 1 (HIV-1) vaccine candidates specifically designed to elicit cytotoxic T-lymphocyte (CTL) responses have entered the pipeline of clinical trials. Evaluating the immunogenicity and potential efficacy of these HIV-1 vaccine candidates is challenging in the face of the extensive viral genetic diversity of circulating strains. Standardized peptide reagents to define the magnitude and potential breadth of the T-cell response, especially to circulating strains of HIV-1, are needed. For this purpose we developed a biometric approach based on T-cell recognition pattern for defining standardized reagents. Circulating strains in the Los Alamos database were evaluated and standardized algorithms to define all potential T-cell epitopes (PTEs) were generated. While many unique PTEs could be identified, a finite number based upon prevalence of circulating strains in the database, which we define as vaccine-important PTEs (VIPs), were used to select a common standardized panel of HIV-1 peptides for CTL-based vaccine evaluation. The usability of PTE peptide set was manifested by detection of Nef-specific CTL responses in HIV-1 subtype B infections.
- Published
- 2006
- Full Text
- View/download PDF